{
  "x402Version": 2,
  "id": 38946,
  "slug": "38946",
  "resource": "https://api.magentlab.com/api/calc/prevail",
  "description": "Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.",
  "type": "http",
  "serviceName": "magent",
  "resourceType": "Agent Service",
  "accepts": [
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "5000",
      "amountUsd": 0.005,
      "maxTimeoutSeconds": 600
    }
  ],
  "outputSchema": {
    "properties": {
      "example": {
        "type": "object"
      },
      "type": {
        "type": "string"
      }
    },
    "required": [
      "type"
    ],
    "type": "object"
  },
  "extensions": {
    "bazaar": {
      "info": {
        "iconUrl": "https://api.magentlab.com/favicon.ico",
        "input": {
          "body": {
            "items": [
              {
                "albumin_g_dl": 4,
                "alp_below_uln": true,
                "bone_mets_lt_10": true,
                "hemoglobin_g_dl": 13,
                "ldh_below_uln": true,
                "months_since_diagnosis": 60,
                "nlr_lt_2_5": true,
                "no_liver_metastases": true,
                "pain_0_to_1": true,
                "psa_ng_ml": 20,
                "treatment_enzalutamide": true
              },
              {
                "albumin_g_dl": 4,
                "alp_below_uln": true,
                "bone_mets_lt_10": true,
                "hemoglobin_g_dl": 13,
                "ldh_below_uln": true,
                "months_since_diagnosis": 60,
                "nlr_lt_2_5": true,
                "no_liver_metastases": true,
                "pain_0_to_1": true,
                "psa_ng_ml": 20,
                "treatment_enzalutamide": true
              }
            ]
          },
          "method": "POST",
          "type": "http"
        },
        "output": {
          "example": {
            "count": 2,
            "items": [
              {
                "albumin_g_dl": 4,
                "alp_below_uln": true,
                "bone_mets_lt_10": true,
                "citation": {
                  "authors": "Armstrong AJ, Lin P, Higano CS, et al.",
                  "doi": "10.1093/annonc/mdy406",
                  "id": "armstrong-2018-prevail",
                  "pmid": "30202945",
                  "source": "Ann Oncol. 2018;29(11):2200-2209",
                  "title": "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer"
                },
                "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
                "formula": "prevail",
                "formula_expression": "lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans",
                "hemoglobin_g_dl": 13,
                "ldh_below_uln": true,
                "linear_predictor": -5.796122,
                "months_since_diagnosis": 60,
                "nlr_lt_2_5": true,
                "no_liver_metastases": true,
                "pain_0_to_1": true,
                "psa_ng_ml": 20,
                "risk_score": -5.796122,
                "treatment_enzalutamide": true
              },
              {
                "albumin_g_dl": 4,
                "alp_below_uln": true,
                "bone_mets_lt_10": true,
                "citation": {
                  "authors": "Armstrong AJ, Lin P, Higano CS, et al.",
                  "doi": "10.1093/annonc/mdy406",
                  "id": "armstrong-2018-prevail",
                  "pmid": "30202945",
                  "source": "Ann Oncol. 2018;29(11):2200-2209",
                  "title": "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer"
                },
                "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
                "formula": "prevail",
                "formula_expression": "lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans",
                "hemoglobin_g_dl": 13,
                "ldh_below_uln": true,
                "linear_predictor": -5.796122,
                "months_since_diagnosis": 60,
                "nlr_lt_2_5": true,
                "no_liver_metastases": true,
                "pain_0_to_1": true,
                "psa_ng_ml": 20,
                "risk_score": -5.796122,
                "treatment_enzalutamide": true
              }
            ],
            "path": "/api/calc/prevail"
          },
          "type": "json"
        }
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "properties": {
          "input": {
            "additionalProperties": false,
            "properties": {
              "body": {
                "additionalProperties": false,
                "properties": {
                  "items": {
                    "items": {
                      "properties": {
                        "albumin_g_dl": {
                          "description": "Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin.",
                          "type": "number"
                        },
                        "alp_below_uln": {
                          "description": "Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥ULN) has HR 0.79. magent does not assay ALP or apply ULN.",
                          "type": "boolean"
                        },
                        "bone_mets_lt_10": {
                          "description": "Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus ≥10) has HR 0.68. magent does not read bone scans.",
                          "type": "boolean"
                        },
                        "hemoglobin_g_dl": {
                          "description": "Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin.",
                          "type": "number"
                        },
                        "ldh_below_uln": {
                          "description": "Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥1×ULN) has HR 0.67. magent does not assay LDH or apply ULN.",
                          "type": "boolean"
                        },
                        "months_since_diagnosis": {
                          "description": "Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval.",
                          "type": "number"
                        },
                        "nlr_lt_2_5": {
                          "description": "Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus ≥2.5) has HR 0.69. magent does not compute NLR from counts.",
                          "type": "boolean"
                        },
                        "no_liver_metastases": {
                          "description": "No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging.",
                          "type": "boolean"
                        },
                        "pain_0_to_1": {
                          "description": "Pain score 0-1 versus ≥2 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus ≥2) has HR 0.77. magent does not assign pain scores.",
                          "type": "boolean"
                        },
                        "psa_ng_ml": {
                          "description": "Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA.",
                          "type": "number"
                        },
                        "treatment_enzalutamide": {
                          "description": "true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order.",
                          "type": "boolean"
                        }
                      },
                      "required": [
                        "albumin_g_dl",
                        "alp_below_uln",
                        "bone_mets_lt_10",
                        "hemoglobin_g_dl",
                        "ldh_below_uln",
                        "nlr_lt_2_5",
                        "pain_0_to_1",
                        "no_liver_metastases",
                        "psa_ng_ml",
                        "months_since_diagnosis",
                        "treatment_enzalutamide"
                      ],
                      "type": "object"
                    },
                    "maxItems": 25,
                    "minItems": 1,
                    "type": "array"
                  }
                },
                "required": [
                  "items"
                ],
                "type": "object"
              },
              "headers": {
                "additionalProperties": {
                  "type": "string"
                },
                "type": "object"
              },
              "method": {
                "const": "POST",
                "type": "string"
              },
              "type": {
                "const": "http",
                "type": "string"
              }
            },
            "required": [
              "type",
              "method"
            ],
            "type": "object"
          },
          "output": {
            "properties": {
              "example": {
                "type": "object"
              },
              "type": {
                "type": "string"
              }
            },
            "required": [
              "type"
            ],
            "type": "object"
          }
        },
        "required": [
          "input"
        ],
        "type": "object"
      }
    }
  },
  "tags": [
    "prevail",
    "mcrpc",
    "prostate-cancer",
    "survival",
    "calculator",
    "bazaar"
  ],
  "sourceHost": "api.magentlab.com",
  "lastUpdated": "2026-10-13T11:32:55.349Z",
  "quality": {
    "calls30d": 5,
    "uniquePayers30d": 2,
    "lastCalledAt": "2026-10-13T11:32:55.215Z"
  },
  "metadata": {
    "serviceName": "magent",
    "extensions": {
      "bazaar": {
        "info": {
          "iconUrl": "https://api.magentlab.com/favicon.ico",
          "input": {
            "body": {
              "items": [
                {
                  "albumin_g_dl": 4,
                  "alp_below_uln": true,
                  "bone_mets_lt_10": true,
                  "hemoglobin_g_dl": 13,
                  "ldh_below_uln": true,
                  "months_since_diagnosis": 60,
                  "nlr_lt_2_5": true,
                  "no_liver_metastases": true,
                  "pain_0_to_1": true,
                  "psa_ng_ml": 20,
                  "treatment_enzalutamide": true
                },
                {
                  "albumin_g_dl": 4,
                  "alp_below_uln": true,
                  "bone_mets_lt_10": true,
                  "hemoglobin_g_dl": 13,
                  "ldh_below_uln": true,
                  "months_since_diagnosis": 60,
                  "nlr_lt_2_5": true,
                  "no_liver_metastases": true,
                  "pain_0_to_1": true,
                  "psa_ng_ml": 20,
                  "treatment_enzalutamide": true
                }
              ]
            },
            "method": "POST",
            "type": "http"
          },
          "output": {
            "example": {
              "count": 2,
              "items": [
                {
                  "albumin_g_dl": 4,
                  "alp_below_uln": true,
                  "bone_mets_lt_10": true,
                  "citation": {
                    "authors": "Armstrong AJ, Lin P, Higano CS, et al.",
                    "doi": "10.1093/annonc/mdy406",
                    "id": "armstrong-2018-prevail",
                    "pmid": "30202945",
                    "source": "Ann Oncol. 2018;29(11):2200-2209",
                    "title": "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer"
                  },
                  "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
                  "formula": "prevail",
                  "formula_expression": "lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans",
                  "hemoglobin_g_dl": 13,
                  "ldh_below_uln": true,
                  "linear_predictor": -5.796122,
                  "months_since_diagnosis": 60,
                  "nlr_lt_2_5": true,
                  "no_liver_metastases": true,
                  "pain_0_to_1": true,
                  "psa_ng_ml": 20,
                  "risk_score": -5.796122,
                  "treatment_enzalutamide": true
                },
                {
                  "albumin_g_dl": 4,
                  "alp_below_uln": true,
                  "bone_mets_lt_10": true,
                  "citation": {
                    "authors": "Armstrong AJ, Lin P, Higano CS, et al.",
                    "doi": "10.1093/annonc/mdy406",
                    "id": "armstrong-2018-prevail",
                    "pmid": "30202945",
                    "source": "Ann Oncol. 2018;29(11):2200-2209",
                    "title": "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer"
                  },
                  "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
                  "formula": "prevail",
                  "formula_expression": "lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans",
                  "hemoglobin_g_dl": 13,
                  "ldh_below_uln": true,
                  "linear_predictor": -5.796122,
                  "months_since_diagnosis": 60,
                  "nlr_lt_2_5": true,
                  "no_liver_metastases": true,
                  "pain_0_to_1": true,
                  "psa_ng_ml": 20,
                  "risk_score": -5.796122,
                  "treatment_enzalutamide": true
                }
              ],
              "path": "/api/calc/prevail"
            },
            "type": "json"
          }
        },
        "schema": {
          "$schema": "https://json-schema.org/draft/2020-12/schema",
          "properties": {
            "input": {
              "additionalProperties": false,
              "properties": {
                "body": {
                  "additionalProperties": false,
                  "properties": {
                    "items": {
                      "items": {
                        "properties": {
                          "albumin_g_dl": {
                            "description": "Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin.",
                            "type": "number"
                          },
                          "alp_below_uln": {
                            "description": "Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥ULN) has HR 0.79. magent does not assay ALP or apply ULN.",
                            "type": "boolean"
                          },
                          "bone_mets_lt_10": {
                            "description": "Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus ≥10) has HR 0.68. magent does not read bone scans.",
                            "type": "boolean"
                          },
                          "hemoglobin_g_dl": {
                            "description": "Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin.",
                            "type": "number"
                          },
                          "ldh_below_uln": {
                            "description": "Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥1×ULN) has HR 0.67. magent does not assay LDH or apply ULN.",
                            "type": "boolean"
                          },
                          "months_since_diagnosis": {
                            "description": "Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval.",
                            "type": "number"
                          },
                          "nlr_lt_2_5": {
                            "description": "Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus ≥2.5) has HR 0.69. magent does not compute NLR from counts.",
                            "type": "boolean"
                          },
                          "no_liver_metastases": {
                            "description": "No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging.",
                            "type": "boolean"
                          },
                          "pain_0_to_1": {
                            "description": "Pain score 0-1 versus ≥2 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus ≥2) has HR 0.77. magent does not assign pain scores.",
                            "type": "boolean"
                          },
                          "psa_ng_ml": {
                            "description": "Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA.",
                            "type": "number"
                          },
                          "treatment_enzalutamide": {
                            "description": "true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order.",
                            "type": "boolean"
                          }
                        },
                        "required": [
                          "albumin_g_dl",
                          "alp_below_uln",
                          "bone_mets_lt_10",
                          "hemoglobin_g_dl",
                          "ldh_below_uln",
                          "nlr_lt_2_5",
                          "pain_0_to_1",
                          "no_liver_metastases",
                          "psa_ng_ml",
                          "months_since_diagnosis",
                          "treatment_enzalutamide"
                        ],
                        "type": "object"
                      },
                      "maxItems": 25,
                      "minItems": 1,
                      "type": "array"
                    }
                  },
                  "required": [
                    "items"
                  ],
                  "type": "object"
                },
                "headers": {
                  "additionalProperties": {
                    "type": "string"
                  },
                  "type": "object"
                },
                "method": {
                  "const": "POST",
                  "type": "string"
                },
                "type": {
                  "const": "http",
                  "type": "string"
                }
              },
              "required": [
                "type",
                "method"
              ],
              "type": "object"
            },
            "output": {
              "properties": {
                "example": {
                  "type": "object"
                },
                "type": {
                  "type": "string"
                }
              },
              "required": [
                "type"
              ],
              "type": "object"
            }
          },
          "required": [
            "input"
          ],
          "type": "object"
        }
      }
    }
  },
  "liveness": {
    "reliability": null
  },
  "verified": false,
  "featured": false,
  "provider": {
    "host": "api.magentlab.com",
    "manifest_name": "api.magentlab.com",
    "source": "cdp-mirror",
    "source_manifest_url": "https://api.cdp.coinbase.com/platform/v2/x402/discovery/resources",
    "submitted_at": "2026-10-14T01:15:01.050Z"
  },
  "exampleResponse": {
    "example": {},
    "type": "string"
  }
}